Go Back

PET/CT for radiotherapy planning in lung cancer


About the Presentation

This seminar on PET/CT for radiotherapy planning in lung cancer will cover the following areas:

  • Background / Impact of PET in NSCLC staging;
  • Radiotherapy planning (RTP) with PET/CT and PET based target volume delineation;
  • Respiratory Motion and PET/CT;
  • PET in adaptive radiotherapy;
  • Non-FDG PET isotopes in RTP;
  • Non-PET based functional imaging;
  • PET for prediction of outcome and for follow-up after RT;
  • PET and SCLC.

On completing this seminar participants should:

  • Appreciate that PET is critical for baseline staging and patient selection for radical therapy;
  • Appreciate that Functional imaging is essential for RTP in both NSCLC and SCLC;
  • Appreciate that PET should be used to guide and inform target volume delineation in NSCLC and SCLC;
  • Be aware of respiratory motion issues in the acquisition of PET/CT for radiotherapy planning;
  • Be aware of potential extended usages of PET such as for follow-up of patients after stereotactic ablative radiotherapy (SABR) in lung cancer.

About the Author

Dr Gerry Hanna

Dr Gerry Hanna is Consultant Clinical Oncologist and Senior Lecturer at the Centre for Cancer Research and Cell Biology, Queen’s University of Belfast. He is involved in the treatment of lung and breast cancer, both with systemic therapy and radiation therapy. He completed a PhD fellowship in 2010 on the topic of PET/CT for target volume delineation in the radiotherapy planning process for patients with lung cancer. In addition to PET/CT for radiation treatment planning his research interests include the use of IMRT in lung cancer, stereotactic radiotherapy for lung cancer, altered fractionation in breast cancer and the use of predictive assays.

 


Presentation with audio
(After unzipping the file, open "story.html" from archive):


Presentation's slides
(PDF):